Clinical Trials Browser

Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × Dermatologic × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04700072 2025-10-28

KEYMAKER-U02

Phase 1/2 Completed

56 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05665595 2025-10-15

KEYVIBE-010

Phase 3 Completed

1,594 enrolled 12 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03715205 2025-08-29

Keynote-593

Phase 4 Completed

150 enrolled 14 charts

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04305041 2025-08-29

KEYMAKER-U02

Phase 1/2 Completed

100 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05432622 2024-01-18

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Completed

95 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02130466 2022-08-01

MK-3475-022

Phase 1/2 Completed

184 enrolled 62 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02983006 2021-10-18

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Phase 1 Completed

12 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01866319 2020-06-02

MK-3475-006

Phase 3 Completed

834 enrolled 13 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01704287 2020-05-18

KEYNOTE 002

Phase 2 Completed

540 enrolled 20 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01295827 2019-12-13

KEYNOTE-001

Phase 1 Completed

1,260 enrolled 45 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase 1 Completed

68 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis